SOUTH CAROLINA – October 25, 2024 – Vova Ida Therapeutics, from Jupiter, F.L., is developing disease-modifying treatments for age-related neurodegenerative disorders. VIT’s lead program is at the IND-enabling stage and focuses on restoration of neuronal nicotinamide adenine dinucleotide (NAD) homeostasis and cell recovery. VIT’s preclinical data and clinical development plan are supported by use of proximal biomarkers that show target engagement and that are relevant to disease pathogenesis.
Solutions
Using its proprietary drug discovery platform, VIT has developed three unique programs addressing the cell’s loss of protein and energy homeostasis leading to degeneration. By tackling upstream causative mechanisms, VIT is developing molecules poised to exhibit profound disease-modifying effects. VIT’s most advanced program, Regenepower, includes two proprietary leads with neuroprotective and regenerative potential.
Strengths
- Decades of Expertise:
- Platform and product company backed by over 30 years of research.
- Leadership Team:
- Small, highly experienced leadership team with backgrounds in science, drug discovery and development, clinical and life sciences business.
- Intellectual Property:
- Extensive patent portfolio comprising eight patent families.
- Comprehensive Strategy
- Holistic approach tackling the root cause of degenerative diseases from different angles.
Meet the Co-Founders
From left to right:
Corinne Lasmezas – Founder and CSO
Adam Milne – CEO
Eric Ende – Executive Chairman